Expert consensus on pharmaceutical practice of children's thrombotic disease

Title: Expert consensus on pharmaceutical practice of children's thrombotic disease
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users: Medicine and clinical pharmacy
Evidence classification method: GRADE classification system
Development unit: 中华医学会临床药学分会;四川省医学科学院&四川省人民医院
Registration time: 2022-11-21
Registration number: PREPARE-2022CN758
Purpose of the guideline: In the Internet and digital era, the growing volume of scientific and technological literature, the increase of scientific research achievements and the limited energy of scholars have limited the panoramic scanning of domestic and foreign research achievements in the drug treatment of children's thrombotic diseases, which makes it impossible to fully understand domestic and foreign research. Quantitative and large-scale data analysis has been unable to meet the needs of scholars to investigate more extensive research achievements. The research value of this expert consensus lies in: theoretically establishing the retrieval strategy of PICO and database, providing theoretical and methodological guidance for data collection, and constructing the recommended classification of antithrombotic therapy for children's thrombotic diseases, with a view to providing different levels of methods and process reference for children's antithrombotic therapy. In practical application, the comparative analysis and summary of antithrombotic therapy for children's thrombotic diseases at home and abroad were carried out, which is helpful to find the differences and gaps in the development of antithrombotic therapy between China and foreign countries, thus providing data support for the research and practice of antithrombotic therapy in China. Based on this, it provides theoretical support and evidence-based evidence for doctors and pharmacists to reasonably select antithrombotic drugs.